Medtronic CRT Devices Improve Therapy Delivery, Cut Costs
Zacks Investment Research | Jun 21, 2017 08:50AM ET
One of the world’s largest medical technology, services and solutions companies, Medtronic plc (NYSE:MDT) has been consistently expanding its core business segments. Keeping in line with this, the company recently announced positive data on cardiac resynchronization therapy (CRT) devices within its Cardiac and Vascular segment.
Data from a latest clinical trial reveals that, Medtronic’s CRT devices, when combined with its proprietary AdaptivCRT and EffectiveCRT algorithms, reduce costs of healthcare system and improve therapy delivery in heart failure patients who also suffer from atrial fibrillation (AF). AF is one of the most common heart rhythm disorders. Notably, it is an irregular or rapid beating of the heart’s upper chambers.
European health-economic analysis based on data from Italy, Spain and U.K demonstrated that lifetime costs for patients treated with AdaptivCRT were lower and life expectancy was extended by an average of four months than patients treated with traditional pacing algorithms.
Also, another analysis based on the CRTee study reveals that Medtronic device-based EffectivCRT during AF algorithm improves left ventricular pacing by 19% in patients with AF in comparison to devices without the technology.
Most of the patients with heart failure do not respond to CRT because they also have AF. The EffectivCRT Diagnostic determines the efficacy of left ventricular pacing automatically. It also adjusts pacing rates during AF algorithm.
Lastly, the economic analysis of Medtronic CRT-defibrillators (CRT-D) reveals as high as nine years of longevity for Claria and Amplia devices, and around eight years for Viva XT CRT-Ds. These are significant expansion in terms of device longivity when compared to previous models. According to Medtronic, improvement in longevity will lead to less device replacements which will further save costs.
Over the last six months, Medtronic has been observed to outperform the Zacks categorized Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.